Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital Capital Medical University Beijing China.
National Clinical Research Center for Cardiovascular Diseases Beijing China.
J Am Heart Assoc. 2024 Oct;13(19):e029252. doi: 10.1161/JAHA.122.029252. Epub 2024 Sep 18.
BACKGROUND: Patients with acute coronary syndrome without standard modifiable cardiovascular risk factors (SMuRFs; hypertension, smoking, dyslipidemia, diabetes) have not been well studied, with little known about their characteristics, quality of care, or outcomes. We sought to systematically analyze patients with ACS without SMuRFs, especially to evaluate the effectiveness of guideline-directed medical therapy for these patients. METHODS AND RESULTS: In the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) project (2014-2019), we examined the presence and absence of SMuRFs and features among 89 462 patients with initial acute coronary syndrome. The main outcome was in-hospital all-cause mortality. Among eligible patients, 11.0% had none of the SMuRFs (SMuRF-less). SMuRF-less patients had higher in-hospital mortality (unadjusted hazard ratio [HR], 1.49 [95% CI, 1.19-1.87]). After adjustment for clinical characteristics and treatments, the associations between SMuRF status and in-hospital mortality persisted (adjusted HR, 1.35 [95% CI, 1.07-1.70]). Guideline-directed optimal medical therapy (receiving angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, and statins) was not associated with lower mortality (adjusted HR, 0.98 [95% CI, 0.58-1.67]) in SMuRF-less patients, unlike the association in patients with SMuRFs (adjusted HR, 0.80 [95% CI, 0.66-0.98]). Sensitivity analyses were consistent with these results. CONCLUSIONS: SMuRF-less patients were associated with an increased risk of in-hospital mortality. Guideline-directed medical therapy was less effective in SMuRF-less patients than in patients with SMuRFs. Dedicated studies are needed to confirm the optimal therapy for SMuRF-less patients. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02306616.
背景:患有不伴有标准可修正心血管风险因素(SMuRFs;高血压、吸烟、血脂异常、糖尿病)的急性冠脉综合征患者的研究还不够充分,对于这些患者的特征、医疗护理质量和结局了解甚少。我们试图系统地分析不伴有 SMuRFs 的 ACS 患者,尤其是评估这些患者的指南指导的药物治疗的效果。
方法和结果:在 CCC-ACS(改善中国心血管疾病管理-急性冠脉综合征)项目(2014-2019 年)中,我们检查了 89462 例初始急性冠脉综合征患者中 SMuRFs 的存在情况和特征。主要结局是院内全因死亡率。在符合条件的患者中,11.0%的患者不伴有任何 SMuRFs(SMuRF-无)。SMuRF-无患者的院内死亡率更高(未经调整的危险比[HR],1.49[95%置信区间,1.19-1.87])。在调整了临床特征和治疗后,SMuRF 状态与院内死亡率之间的关联仍然存在(调整后的 HR,1.35[95%置信区间,1.07-1.70])。指南指导的最佳药物治疗(接受血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂、β受体阻滞剂和他汀类药物)与 SMuRF-无患者的死亡率降低无关(调整后的 HR,0.98[95%置信区间,0.58-1.67]),而与伴有 SMuRFs 的患者的死亡率降低相关(调整后的 HR,0.80[95%置信区间,0.66-0.98])。敏感性分析结果与这些结果一致。
结论:SMuRF-无患者与院内死亡率增加相关。指南指导的药物治疗在 SMuRF-无患者中的效果不如伴有 SMuRFs 的患者。需要专门的研究来确定 SMuRF-无患者的最佳治疗方法。
Front Endocrinol (Lausanne). 2025-5-27
Am J Respir Crit Care Med. 2022-1-1
Eur Heart J. 2021-10-1